Multiple Sclerosis (MS) is an autoimmune inflammatory disease that presents clinically with a range of symptoms including motor, sensory, and cognitive dysfunction as well as demyelination and lesion formation in brain and spinal cord. A variety of animal models of MS have been developed that share many of the pathological hallmarks of MS including motor deficits (ascending paralysis), demyelination and axonal damage of central nervous system (CNS) tissue. In recent years, neuropathic pain has been recognized as a prevalent symptom of MS in a majority of patients. To date, there have been very few investigations into sensory disturbances in animal models of MS. The current work contains the first assessment of hind paw mechanical allodynia (von Frey test) over the course of a relapsing-remitting myelin oligodendrocyte glycoprotein induced experimental autoimmune encephalomyelitis (MOG-EAE) rat model of MS and establishes the utility of this model in examining autoimmune induced sensory dysfunction. We demonstrate periods of both decreased responsiveness to touch that precedes the onset of hind limb paralysis, and increased responsiveness (allodynia) that occurs during the period of motor deficit amelioration traditionally referred to as symptom remission. Furthermore, we tested the ability of our recently characterized anti-inflammatory IL-10 gene therapy to treat the autoimmune inflammation induced behavioral symptoms and tissue histopathological changes. This therapy is shown here to reverse inflammation induced paralysis, to reduce disease associated reduction in sensitivity to touch, to prevent the onset of allodynia, to reverse disease associated loss of body weight, and to suppress CNS glial activation associated with disease progression in this model.
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Introduction
Multiple Sclerosis (MS) is an autoimmune disease affecting at least 1 in 1000 people in the US and is anticipated to become substantially more prevalent in coming years (Hirtz et al., 2007) . This debilitating disease involves an attack by the immune system against antigens of the central nervous system (CNS), especially antigens derived from oligodendrocytes that constitute the myelin sheaths surrounding axons. Initiating factors that cause the disease are poorly understood and are thought to involve a genetic predisposition (Kenealy et al., 2003) as well as environmental influences (Marrie, 2004) .
In addition to the auto-aggressive T-cells that characterize MS (Martin et al., 1992) , marked activation of glia (microglia and astrocytes) occurs in MS patients in both the spinal cord and brain (Petzold et al., 2002; Gray et al., 2008) . This results in inflammation involving pro-inflammatory cytokines and chemokines (Ozenci et al., 2002; Szczucinski and Losy, 2007) . These inflammatory molecules may profoundly change signaling properties of neurons (Katsuki et al., 1990; Cunningham et al., 1996; Viviani et al., 2003) and lead to demyelination and axonal loss, two hallmarks of MS (Bruck, 2005; Hendriks et al., 2005) .
Inflammation induced disruption of neuronal signaling in MS patients leads to a diverse array of motor, cognitive, and sensory symptoms. Motor dysfunctions are striking and include spasticity, loss of normal gait, paresis, and progressive ascending paralysis. Decreased sensitivity to touch is a common early sensory symptom
